CURE Funding Opportunities

and GMaP Resources

for UMass Boston & Dana Farber

Cancer Institute PACHE ESIs

March 06, 2019

Mary Ann S. Van Duyn, PhD

Hana M. Odeh, Ph.D

2

The National Cancer Institute (NCI)

NCI Shady Grove NIH Clinical Center Frederick National Lab.

for Cancer ResearchNCI-Designated Cancer Centers

3

NCI Center to Reduce Cancer Health Disparities (CRCHD)

▪ Strengthens the NCI cancer research portfolio in basic, clinical,

translational, and population-based research to address cancer

health disparities through collaborations across NCI

▪ Advises NCI leadership on strategic priorities, program direction,

and scientific policy to strengthen cancer disparities research,

diversity training, women’s health and sexual and gender minority

opportunities

▪ Leads NCI’s efforts to increase workforce diversity through the

training of students and investigators from diverse backgrounds

4

T R A I N E E S

Increase the size

of the talent pool

Emphasize scientific

areas of

greatest need

Expand and

extend the period

of training

Continuing Umbrella of Research Experiences (CURE)

Post-

baccalaureate

Grades

6-12

Undergraduate

Predoctoral Investigators

PostdoctoralPost

Masters

5

Celebrating 21 years of the CURE Program! June 2017

6

NCI Diversity Supplements (PA-16-288)

▪ Supports mentored research training and career

development of individuals in cancer research

▪ Individuals must be from underrepresented populations:

race/ethnicity, disability, and/or disadvantaged background

▪ Provides support for salary, tuition, limited supplies, and

travel to meetings/conferences

▪ 2 Due dates: Oct 1–Dec1 and Feb 1–March 30

▪ Contact: Drs. Alison Lin and Sara Hargrave,

CUREsupplements@nih.gov

Post- doctoralEarly Stage Investigator

Pre-doctoral

Postbac & Post Masters

High SchoolUnder-

graduateMiddle School

7

K01 Mentored Research Scientist Development Award

to Promote Diversity

▪ Provides protected time and salary support for 3-5 years of

intensive training and research

▪ Individuals must be from underrepresented populations:

race/ethnicity, disability, and/or disadvantaged background

▪ All cancer-related research; Provides support for salary, as well as

R&D support

▪ 3 Due dates: Feb 12, June 12, Oct 12

▪ Contact: Dr. Abigail Soyombo, abigail.soyombo@nih.gov

Post- doctoralEarly Stage Investigator

Pre-doctoral

Postbac & Post Masters

High SchoolUnder-

graduateMiddle School

8

NCI K Awards supported by CRCHD

K

Award

Mentored or

Non-

Mentored

Research FocusMax

Salary

Max

R&D

Support

Duration

K01 MentoredAll Cancer-Related

Research$100k

$30k 3-5 years

K22 Non-Mentored $50k 3 years

K08 Mentored

Clinical, Translational

& Patient-Oriented

Research

$189k $50k 3-5 years

Application Due dates: February 12, June 12, October 12

Institutional Eligibility Certification Letter must be submitted with the application

9

Start early! Sample time line

Submission

Deadline

1 Month

Prior

3 Months (DS)

6-8 Months (Ks)

Prior

5 Months (DS)

8-12 Months (Ks)

Prior

• Identify

mentor/candidate

• Match interests

• Plan application

• Contact NCI

Program Director

• Write application

• Ask people to

review

• Revise and revise

• Assemble

application

components

• Finalize

• Start submission

process

• Remember

institution

deadlines

• Leave room for

submission

logistics issues

10

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (PAR-15-053)

▪ Mechanism: R21

▪ Goals: To enhance the diversity of the NCI-funded research workforce while

supporting eligible researchers to develop preliminary data for competitive

R01 proposals.

▪ Eligibility: Applicants must be from underrepresented populations AND

cannot have a previous R01 award (or grant over $175k direct cost per

year).

▪ Research focus: Basic biology of cancer

▪ Contact: Dr. Elena Schwartz, elena.schwartz@nih.gov

11

R21 Diversity in Science and Grantees

Using genetic ancestry to study breast cancer risks in US Latinas

“As I was transitioning to independence, the R21 allowed me to complement my research agenda and to explore a new area of research.”

Laura Fejerman, PhD, University of California San Francisco

Using a VLP vaccine to prevent EBV-associated malignancies in Burkitt‘s lymphoma in African populations

“I really appreciated the two R21 funding as they allowed my laboratory to approach our experimental plan boldly very early on.”

Javier Gordon Ogembo, PhD, City of Hope

Conducting genomic analyses to study gastric cancer in H/L populations

The R21 represented a crucial springboard to launch my career and provided me with support when I needed it the most. The data and resources generated was crucial to support two grants (R01 and U54).

Luis Carvajal Carmona, PhD, University of California at Davis

12

Basic Research in Cancer Health Disparities (CHD)

PAR-18-655: Exploratory/Developmental Grants Program for Basic Cancer

Research in CHD (R21)

Purpose: Basic research studies investigating biological/genetic causes of CHDs

Eligibility: Open

Awards: Supports exploratory mechanistic and feasibility studies for up to 2 years

Award budget: $ 275,000 direct costs up to two years; no more than $200,000 in direct costs in any

given year

Due dates: June 18, 2019 and November 2019 (also, June 18 and Nov 18 2020)

Contact: Dr. Tiffany Wallace, tiffany.wallace@nih.gov

PAR-18-654: Basic Cancer Research in CHD (R01)

Purpose: Companion FOA for the above R21

Awards: Supports more advanced mechanistic studies that result from preliminary studies/data for up

to 5 years

Award budget: Budget is not limited, but must be well justified

13

R21 Basic CHD Investigator and Research Highlights

• “Host-environment interactions in colorectal

cancer disparities” (R21)

• “Colonic responses to vitamin D and aspirin in

AA and EAs” (R01)

• Investigating how environmental factors, such

as aspirin and Vitamin D, influence cancer risk

and development, particularly in respect to

African American CRC patients

• Publication in Gastroenterology (IF: 20)

Sonia Kupfer, MD | R21 (2017), R01 (2018)

• “PDE4B and pharmacoethnicity of childhood

leukemia” (R21)

• “ARID5B and disparities of childhood leukemia”

(U01)

• Investigating novel biological mechanisms

responsible for racial disparities in ALL and

enable the development of therapeutic

approaches to overcome racial gaps

• Publications in Nature Comm (IF: 11), J Clin

Oncology (IF: 18), Cancer Cell (IF: 22)

Jun J. Yang, PhD | R21 (2011), U01 (2014)

• “Genetic Mechanisms of Survivorship Disparities

after Unrelated HCT” (U01)

• “Immunogenetics of Outcomes Disparities after

Allogeneic HCT” (R01)

• Investigating how genetic variants affect the success

of transplantation for patients of diverse

ancestries, with the goal of reducing risks via

individualized treatment options

• Publications in J Clinical Oncology (IF: 26), Blood

(IF: 10)

Effie Petersdorf, MD | U01 (2011), R01 (2018)

• “The DARC side of Breast Cancer” (R21)

• Investigating the role of African ancestry in

tumor progression with a focus on the tumor

microenvironment and immunological

responses to tumor progression

• Publications in PloS One and recent plenary

speaker at AACR Cancer Disparities Meeting

Melissa Davis, PhD | R21 (2017), R01 application in prep

14

Other Research FOAs that may be of interest

▪ PAR-18-869: Modular R01s in Cancer Control and Population Sciences (R01 Clinical

Trial Optional)▪ Promote a diversity of research topics and scientific challenges in the populations sciences that lend

themselves to a shorter time span and reduced budget.

▪ ESIs encouraged to apply.

▪ Due Dates: Nov 7, 2019, March 6, 2020

▪ Budget: Up to $250,000 direct costs annually for up to 5 years

▪ Contact: Scott Rogers, MPH, rogerssc@mail.nih.gov

▪ RFA-CA-19-020: Advanced Development and Validation of Emerging Molecular and

Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical

Trials Not Allowed) (R33)▪ Supports exploratory research projects focused on further development and validation of emerging

technologies offering novel capabilities for targeting, probing or assessing molecular and cellular

features of cancer biology for basic or clinical cancer research.

▪ Due Dates: May 28, 2019, Sept 27, 2019

▪ Budget: Up to $300,000 direct costs annually for up to 3 years

▪ Contact: Tony Dickherber, PhD, dickherberaj@mail.nih.gov

15

FY18 New: Administrative Supplements to Support Cancer Disparity Collaborative Research

PA-18-842: Trans-NCI funding opportunity with the participation of DCB, DCCPS, DCP, DCTD

and CRCHD to promote cancer health disparities research

Purpose:

• Promotes collaborative research between non-cancer disparities researchers (i.e.

applicant/parent grant PI) and investigators with cancer disparities expertise (i.e.

collaborator)

• Accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging

areas

Budget: $150K direct costs a year/for up to 2 years

FOA published: June 2018

Application Due Dates: September 10, 2018; September 10, 2019; September 10, 2020

Contact: Dr. Elizabeth Perruccio, liz.perruccio@nih.gov

16

Getting Started: Connect with CRCHD Training Navigator!

▪ Help with identifying training opportunities that you may be interested in

▪ Help with identifying a laboratory/mentor who can work with you

▪ Introduce you to an expert in CRCHD who can personally help you and your

mentor as you develop your application

▪ Share NIH and NCI resources that can help you prepare an excellent

application

▪ Introduce you to the GMaP Region 4 Regional Coordinator, Carrie Norbeck, for

connection to the GMaP Network (carrie.norbeck@fccc.edu)

Contact me, Hana Odeh, PhD

hana.odeh@nih.gov

240-276-5572

Looking forward to hearing from you!

17

•Monthly e-newsletter

• Funding opportunity announcements

• Job Announcements

•NIH/NCI career development opportunities

Information

•Conference meet-ups

•Regional peer matching

•Mentor-mentee Matches

•Partnership Development

Interpersonal

•Webinars

•Workshops

•Travel Scholarships

•Pilot Grants

•Expert Application Review

Career/Professional Support

•Researcher Connections

•Regional Resources and Tools

Regional Resources

Geographic Management of Cancer Health Disparities Program: Provides Network of Support

18

Get Connected and Engaged!

▪ Contact Hana Odeh, PhD at

hana.odeh@nih.gov or 240-276-5572

▪ Connect with CRCHD on social media:

@ncicrchd

NCI CRCHD

▪ Visit us online: crchd.cancer.gov

20

Other Disparities Research FOAs▪ PAR-17-150/151: Mechanisms of Disparities in Chronic Liver Diseases and Cancer

(R21/R01)▪ Trans-NIH FOA (NIMHD, NCI, and NIAAA)

▪ NCI DOCs: CRCHD, DCP, DCCPS, DCB

▪ Understand etiologic factors and the underlying mechanisms responsible for chronic liver diseases

and cancer disparities among racial/ethnic minority and socioeconomically disadvantaged

populations.

Contact: Dr. Emmanuel Taylor PhD, emmanuel.taylor@nih.gov

▪ PAR-19-018/19: Mechanisms of Disparities in Etiology and Outcomes of Lung

Cancer in the U.S: The Role of Risk and Protective Factors▪ Trans-NIH FOA (NIMHD and NCI)

▪ NCI DOCs: CRCHD, DCB, DCP, DCCPS, DCTD

▪ Understand the underlying causal factors and mechanisms that result in lung cancer disparities in

U.S. health disparity populations.

▪ Posted: October, 2018; Submission Date: February, 2019

Contact: Dr. Anil Wali, anil.wali@nih.gov